Goldman Sachs on Cardiovascular Devices: LVAD Assets Look Mispriced; Upgrading THOR, Initiating HTWR

Go back to Goldman Sachs on Cardiovascular Devices: LVAD Assets Look Mispriced; Upgrading THOR, Initiating HTWR